Search

Displaying results 4271 - 4280 of 10000 in total
  1. Drug

    Stevioside

    go.drugbank.com/drugs/DB16882
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    NCX 1022

    go.drugbank.com/drugs/DB05410
    Experimental

    NCX is an NO-releasing derivative of hydrocortisone.

  3. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    mutations in the kinase domain of FGFR. … It was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of cholangiocarcinoma and 20-35% of urothelial cancers, respectively.

  4. Drug

    ANA971

    go.drugbank.com/drugs/DB05127
    Experimental

    ANA971 resulted in higher levels of isatoribine in the blood than were present after oral administration of isatoribine itself. … ANA971, an orally administered prodrug of isatoribine. Isatoribine is a nucleoside analog in development for the treatment of chronic hepatitis C virus (HCV) infection.

  5. Drug

    Metacycline

    go.drugbank.com/drugs/DB00931
    Approved

    A broad-spectrum semisynthetic antibiotic related to tetracycline but excreted more slowly and maintaining effective blood levels for a more extended period.

  6. Drug

    FX06

    go.drugbank.com/drugs/DB05685
    Investigational

    FX06 has proven safe in acute and subchronic toxicological studies and recently entered clinical development. It is being developed by Fibrex Medical Inc. … FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells.

  7. Drug

    XL784

    go.drugbank.com/drugs/DB04991
    Investigational

    XL784 is a potent inhibitor of the ADAM-10 metalloprotease enzyme, a target of significant interest because of its important role in blood vessel formation and cell proliferation. … It is being developed by Exelixis, Inc.

  8. Drug

    Nifedipine

    go.drugbank.com/drugs/DB01115
    ApprovedInvestigational

    [A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972. … [A190273] The most popular of the third generation dihydropyridines is [amlodipine].[A190273] Nifedipine was granted FDA approval on 31 December 1981.[L11383]

  9. Drug

    Magnesium trisilicate

    go.drugbank.com/drugs/DB09281
    Approved

    Magnesium trisilicate is an inorganic compound that is used as an antacid in the treatment of peptic ulcers.

  10. Drug

    TBC-3711

    go.drugbank.com/drugs/DB05407
    Investigational

    TBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals.